07.11.2012 • News

Hospira Posts Quarterly Profit Vs Year-Ago Loss

Hospira on Wednesday posted a net profit for the third quarter compared with a year-earlier loss as sales rose slightly, and backed its outlook for the full year.

Net earnings were $1.2 million, or 1 cent per share, versus a net loss of $88.9 million, or 54 cents per share, in the 2011 quarter.

Excluding items, earnings were 47 Cents per share. On that basis, analysts on average were expecting earnings of 45 cents.

Sales rose 1.8% to $994.0 million from $976.7 million a year before.

Hospira, a maker of specialty injectable pharmaceuticals and drug pumps, said it continues to expect 2012 net sales to show a fall of 1% to a rise of 2%, excluding the impact of foreign currency.

It forecast full-year earnings per share, excluding items, of $2.00.

 

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read